Voltarra Pharmaceuticals has appointed Richard Becker as CEO.
Becker brings more than 20 years’ experience to the US biopharma, including senior commercial roles at Alcon, Merck, Novartis, OSI, Bayer and BASF.
In his new role, he leads a company with a pipeline of drugs for rheumatology, central nervous system oncology and immunology.
Voltarra’s lead product is VOLT01, which is in late-stage trials for the treatment of osteoarthritis.
Becker said: “The broad portfolio will allow Voltarra Pharmaceuticals to capitalise on development synergies and favourably position the company with external customers. We are extremely excited about the pipeline as well as future plans for a partner in taking VOLT01 to the next stage.”